Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study.

Lim TH, Gane E, Moyes C, Borman B, Cunningham C.

Gut. 2014 Jul 8. pii: gutjnl-2013-306247. doi: 10.1136/gutjnl-2013-306247. [Epub ahead of print]

PMID:
25006011
[PubMed - as supplied by publisher]
2.

The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis.

Ow MM, de Zoysa JR, Gane EJ.

N Z Med J. 2014 Jun 20;127(1396):34-42.

PMID:
24997462
[PubMed - in process]
3.

No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-resistant Chronic Hepatitis B.

Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM.

Clin Gastroenterol Hepatol. 2014 Jun 11. pii: S1542-3565(14)00821-0. doi: 10.1016/j.cgh.2014.05.024. [Epub ahead of print]

PMID:
24929235
[PubMed - as supplied by publisher]
4.

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.

Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):761-73. doi: 10.1097/MEG.0000000000000084.

PMID:
24901821
[PubMed - in process]
5.

Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.

Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, Miller MD, Kitrinos KM.

J Med Virol. 2014 Sep;86(9):1473-81. doi: 10.1002/jmv.23982. Epub 2014 May 23.

PMID:
24861361
[PubMed - in process]
6.

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.

Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Zhou J, Yetzer ES, Ballester R, Dwyer C, Tong X, Nájera I, Bertasso A, Hammond J, Kindrick A, Morcos PN, Smith P, Stancic S, Shulman NS.

Liver Int. 2014 May 10. doi: 10.1111/liv.12588. [Epub ahead of print]

PMID:
24814388
[PubMed - as supplied by publisher]
7.

Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".

Gane EJ, Agarwal K.

Am J Transplant. 2014 May;14(5):994-1002. doi: 10.1111/ajt.12714. Epub 2014 Apr 14.

PMID:
24730431
[PubMed - in process]
8.

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.

Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL.

Hepatology. 2014 Jun;59(6):2161-9. doi: 10.1002/hep.27161. Epub 2014 Apr 30.

PMID:
24710669
[PubMed - in process]
9.

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.

Gastroenterology. 2014 Jun;146(7):1669-79.e3. doi: 10.1053/j.gastro.2014.02.051. Epub 2014 Mar 3.

PMID:
24602923
[PubMed - indexed for MEDLINE]
Free Article
10.

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ.

Gastroenterology. 2014 May;146(5):1240-8. doi: 10.1053/j.gastro.2014.01.044. Epub 2014 Jan 23.

PMID:
24462735
[PubMed - indexed for MEDLINE]
11.

REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C.

Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R; REFINE Study Group.

Am J Transplant. 2014 Mar;14(3):635-46. doi: 10.1111/ajt.12620. Epub 2014 Jan 23.

PMID:
24456049
[PubMed - in process]
12.

Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation.

Dare AJ, Plank LD, Phillips AR, Gane EJ, Harrison B, Orr D, Jiang Y, Bartlett AS.

Liver Transpl. 2014 Mar;20(3):281-90. doi: 10.1002/lt.23818.

PMID:
24395145
[PubMed - in process]
13.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E.

Gastroenterology. 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028. Epub 2013 Dec 22.

PMID:
24368224
[PubMed - indexed for MEDLINE]
14.

Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C).

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S.

J Hepatol. 2014 Apr;60(4):741-7. doi: 10.1016/j.jhep.2013.12.006. Epub 2013 Dec 11.

PMID:
24333184
[PubMed - in process]
15.

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-1359.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.

PMID:
24316172
[PubMed - in process]
16.

Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.

Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS.

Antimicrob Agents Chemother. 2014 Feb;58(2):1136-45. doi: 10.1128/AAC.01515-13. Epub 2013 Dec 2.

PMID:
24295986
[PubMed - in process]
17.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS.

Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007. Epub 2013 Nov 18.

PMID:
24262278
[PubMed - indexed for MEDLINE]
18.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M.

Gastroenterology. 2014 Feb;146(2):430-41.e6. doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.

PMID:
24184810
[PubMed - indexed for MEDLINE]
19.

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.

PMID:
24120953
[PubMed - in process]
20.

Telbivudine improves renal function in patients with chronic hepatitis B.

Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A.

Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.

PMID:
24067879
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk